Ilsung Pharm (003120) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ilsung Pharm (003120) has a cash flow conversion efficiency ratio of -0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-371.10 Million ≈ $-251.49K USD) by net assets (₩376.56 Billion ≈ $255.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ilsung Pharm - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Ilsung Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Ilsung Pharm carry for a breakdown of total debt and financial obligations.
Ilsung Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ilsung Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DORO AB
ST:DORO
|
-0.017x |
|
Chateau International Development Co Ltd
TW:2722
|
0.005x |
|
EcoFirst Consolidated Bhd
KLSE:3557
|
0.008x |
|
Ruentex Materials Co Ltd
TW:8463
|
0.186x |
|
Allcargo Gati Limited
NSE:ACLGATI
|
N/A |
|
RS Automation Co.Ltd
KQ:140670
|
0.028x |
|
Kortek Corporation
KQ:052330
|
-0.006x |
|
Atinum Investment Co. Ltd
KQ:021080
|
0.098x |
Annual Cash Flow Conversion Efficiency for Ilsung Pharm (2013–2024)
The table below shows the annual cash flow conversion efficiency of Ilsung Pharm from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Ilsung Pharm market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩385.13 Billion ≈ $261.00 Million |
₩-4.26 Billion ≈ $-2.88 Million |
-0.011x | +89.80% |
| 2023-12-31 | ₩382.75 Billion ≈ $259.39 Million |
₩-41.47 Billion ≈ $-28.11 Million |
-0.108x | -23.91% |
| 2022-12-31 | ₩445.57 Billion ≈ $301.95 Million |
₩-38.97 Billion ≈ $-26.41 Million |
-0.087x | -630.33% |
| 2021-12-31 | ₩345.91 Billion ≈ $234.42 Million |
₩5.70 Billion ≈ $3.87 Million |
0.016x | +267.94% |
| 2020-12-31 | ₩347.48 Billion ≈ $235.48 Million |
₩1.56 Billion ≈ $1.06 Million |
0.004x | -64.72% |
| 2019-12-31 | ₩345.49 Billion ≈ $234.13 Million |
₩4.39 Billion ≈ $2.97 Million |
0.013x | -72.70% |
| 2018-12-31 | ₩324.34 Billion ≈ $219.80 Million |
₩15.09 Billion ≈ $10.23 Million |
0.047x | +47.86% |
| 2017-12-31 | ₩322.83 Billion ≈ $218.77 Million |
₩10.16 Billion ≈ $6.88 Million |
0.031x | +132.48% |
| 2016-12-31 | ₩320.10 Billion ≈ $216.93 Million |
₩-31.01 Billion ≈ $-21.02 Million |
-0.097x | -610.55% |
| 2015-12-31 | ₩318.34 Billion ≈ $215.74 Million |
₩6.04 Billion ≈ $4.09 Million |
0.019x | +48.84% |
| 2014-12-31 | ₩328.68 Billion ≈ $222.74 Million |
₩4.19 Billion ≈ $2.84 Million |
0.013x | -18.74% |
| 2013-12-31 | ₩322.74 Billion ≈ $218.72 Million |
₩5.06 Billion ≈ $3.43 Million |
0.016x | -- |
About Ilsung Pharm
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, dige… Read more